A team of researchers at Washington University School of Medicine have developed a deep learning model that is capable of classifying a brain tumour as one of six common types using a single 3D MRI scan, according to a study published in Radiology: Artificial Intelligence.
‘This is the first study to address the most common intracranial tumours and to directly determine the tumour class or the absence of tumour from a 3D MRI volume,’ said Satrajit Chakrabarty, a doctoral student under the supervision of Aristeidis Sotiras, PhD, and Daniel Marcus, PhD, in Mallinckrodt Institute of Radiology’s Computational Imaging Lab at Washington University School of Medicine in St Louis, Missouri.
The six most common intracranial tumour types are high-grade glioma, low-grade glioma, brain metastases, meningioma, pituitary adenoma, and acoustic neuroma. Each was documented through histopathology, which requires surgically removing tissue from the site of a suspected cancer and examining it under a microscope.
According to Chakrabarty, machine and deep learning approaches using MRI data could potentially automate the detection and classification of brain tumours.
‘Non-invasive MRI may be used as a complement, or in some cases, as an alternative to histopathologic examination,’ he said.
To build their machine learning model, called a convolutional neural network, Chakrabarty and researchers from Mallinckrodt Institute of Radiology developed a large, multi-institutional dataset of intracranial 3D MRI scans from four publicly available sources. In addition to the institution’s own internal data, the team obtained pre-operative, post-contrast T1-weighted MRI scans from the Brain Tumor Image Segmentation, The Cancer Genome Atlas Glioblastoma Multiforme, and The Cancer Genome Atlas Low Grade Glioma.
The researchers divided a total of 2,105 scans into three subsets of data: 1,396 for training, 361 for internal testing and 348 for external testing. The first set of MRI scans was used to train the convolutional neural network to discriminate between healthy scans and scans with tumours, and to classify tumours by type. The researchers evaluated the performance of the model using data from both the internal and external MRI scans.
Using the internal testing data, the model achieved an accuracy of 93.35% (337 of 361) across seven imaging classes (a healthy class and six tumour classes). Sensitivities ranged from 91% to 100%, and positive predictive value – or the probability that patients with a positive screening test truly have the disease – ranged from 85–100%. Negative predictive values, or the probability that patients with a negative screening test truly don’t have the disease, ranged from 98% to 100% across all classes. Network attention overlapped with the tumour areas for all tumour types.
For the external test dataset, which included only two tumour types (high-grade glioma and low-grade glioma), the model had an accuracy of 91.95%.
‘These results suggest that deep learning is a promising approach for automated classification and evaluation of brain tumours,’ Chakrabarty said. ‘The model achieved high accuracy on a heterogeneous dataset and showed excellent generalisation capabilities on unseen testing data.’
Chakrabarty said the 3D deep learning model comes closer to the goal of an end-to-end, automated workflow by improving upon existing 2D approaches, which require radiologists to manually delineate, or characterise, the tumour area on an MRI scan before machine processing. The convolutional neural network eliminates the tedious and labor-intensive step of tumour segmentation prior to classification.
Dr Sotiras, a co-developer of the model, said it can be extended to other brain tumour types or neurological disorders, potentially providing a pathway to augment much of the neuroradiology workflow.
‘This network is the first step toward developing an artificial intelligence-augmented radiology workflow that can support image interpretation by providing quantitative information and statistics,’ Chakrabarty added.
Psychreg is mainly for information purposes only; materials on this website are not intended to be a substitute for professional advice. Don’t disregard professional advice or delay in seeking treatment because of what you have read on this website. Read our full disclaimer.